Now Available! | Check out UMR’s 2025 Annual Economic Report and State Toolkits today
Mark Your Calendars! | UMR's 2025 Annual Report is Coming Soon!
NIH Research 101 | UMR Answers Common Questions About NIH Research in this New Fact Sheet Series
Rural State Analysis | UMR's 2023 Report Reveals the Exponential Impact of NIH Research Funding in 7 Rural States
Why Invest in NIH Research? | UMR Offers Fact Sheets Explaining Why Congress Must #keepNIHstrong
Privacy Policy © 2025 United For Medical Research. All Rights Reserved.

A participant in the NIH 2019-2020 Medical Research Scholars Program.

Photo Credit: National Institutes of Health

About This Photo

BD Launches Combination Test for COVID-19, Influenza A/B and Respiratory Syncytial Virus

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced that the BD MAX™ Respiratory Viral Panel (RVP), a new molecular diagnostic combination test for SARS-CoV-2, Influenza A + B and Respiratory Syncytial Virus (RSV), has been CE marked to the IVD directive 98/79/EC.